bluebird bio, Inc. (NASDAQ:BLUE) insider Eric Sullivan sold 861 shares of the firm’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $93.83, for a total transaction of $80,787.63. Following the completion of the sale, the insider now owns 5,924 shares of the company’s stock, valued at approximately $555,848.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Eric Sullivan also recently made the following trade(s):
- On Thursday, June 29th, Eric Sullivan sold 6,787 shares of bluebird bio stock. The shares were sold at an average price of $108.96, for a total transaction of $739,511.52.
bluebird bio, Inc. (NASDAQ:BLUE) traded down 0.86% during mid-day trading on Friday, reaching $92.45. 497,130 shares of the company’s stock traded hands. bluebird bio, Inc. has a 52-week low of $37.05 and a 52-week high of $123.75. The company’s market capitalization is $4.21 billion. The company has a 50-day moving average of $96.49 and a 200-day moving average of $91.07.
bluebird bio (NASDAQ:BLUE) last released its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.66) by $0.07. bluebird bio had a negative net margin of 1,080.59% and a negative return on equity of 32.19%. The firm had revenue of $16.70 million for the quarter, compared to analyst estimates of $6.29 million. During the same quarter in the prior year, the firm earned ($1.59) EPS. The firm’s revenue was up 977.4% compared to the same quarter last year. Equities research analysts expect that bluebird bio, Inc. will post ($6.78) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “bluebird bio, Inc. (NASDAQ:BLUE) Insider Sells $80,787.63 in Stock” was published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.com-unik.info/2017/08/19/insider-selling-bluebird-bio-inc-nasdaqblue-insider-sells-861-shares-of-stock-updated.html.
A number of equities research analysts recently commented on BLUE shares. Maxim Group upgraded shares of bluebird bio from a “hold” rating to a “buy” rating and set a $100.00 price objective for the company in a research report on Friday, June 2nd. BTIG Research restated a “buy” rating and issued a $112.00 price objective on shares of bluebird bio in a research report on Thursday, June 1st. Standpoint Research started coverage on shares of bluebird bio in a research report on Tuesday, May 30th. They issued a “buy” rating and a $110.00 price objective for the company. BMO Capital Markets reaffirmed a “buy” rating and issued a $108.00 target price on shares of bluebird bio in a report on Tuesday, June 6th. Finally, Janney Montgomery Scott increased their target price on shares of bluebird bio from $81.00 to $125.00 and gave the company a “buy” rating in a report on Wednesday, June 7th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $100.74.
Several large investors have recently added to or reduced their stakes in BLUE. QS Investors LLC raised its stake in bluebird bio by 70.7% in the second quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock worth $127,000 after buying an additional 500 shares in the last quarter. Bank of Montreal Can raised its stake in bluebird bio by 118.9% in the second quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock worth $176,000 after buying an additional 911 shares in the last quarter. Turner Investments LLC purchased a new stake in bluebird bio during the second quarter worth about $184,000. SG Americas Securities LLC raised its position in bluebird bio by 17.9% in the second quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 295 shares in the last quarter. Finally, Fairfield Bush & CO. bought a new position in bluebird bio during the second quarter valued at $210,000.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
What are top analysts saying about bluebird bio Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for bluebird bio Inc. and related companies.